The Global Vaccines Market is expected to reach US$ 64,538.4 Mn in 2027 from US$ 36,998.8 in 2018 and estimated to grow with a CAGR of 6.5% from 2019-2027

by Sameer Joshi or 05-Apr-2019
     Request For Sample

Report : Vaccines Market to 2027- Global Analysis and Forecasts by Technology (Recombinant Vaccines, Conjugate Vaccines, Live Attenuated Vaccines, Inactivated and Subunit Vaccines, and Toxoid Vaccines); Disease Indication (DTP (Diphtheria Tetanus toxoids and Pertussis), Influenza, Hepatitis, Respiratory Syncytial Virus (RSV), and Other Diseases); Route of Administration (Oral, Injectable, and Other Routes of Administration); Patient Type (Pediatric Patients, and Adult Patients) and Geography

Pediatric segment is expected to drive the growth of the global vaccines market by patient type

According to a new market research study titled 'Vaccines Market - Global Analysis and Forecasts by Technology, Disease Indication, Route of Administration, and Patient Type. The global vaccines market is expected to reach US$ 64,538.4 Mn in 2027 from US$ 36,998.8 in 2018. The market is estimated to grow with a CAGR of 6.5% from 2019-2027. The report highlights the trends prevalent in the global vaccines market and the factors driving the market along with those that act as deterrents to its growth. The market is expected to grow due to due to growing focus on immunization programs, increasing support for vaccine development, rising prevalence of infectious diseases.

In addition to the funds from traditional research-funding institutions, the Gates Foundation has invested hundreds of millions of dollars in R&D of new vaccines against the leading killers of children and adults everywhere. GAVI has established public-private partnerships to accelerate late-stage development and introduction of priority vaccines against diseases such as rotavirus and pneumococcus. These partnerships are designed to work with governments, donors, and industry to streamline demand, supply, and financing decisions. They coordinate and fund the efforts of partners supporting national decision makers whether to introduce these new products, ensuring a reliable and sustainable supply of affordable vaccine to developing countries, and reducing risks and creating incentives for private investment to ensure access to the product. Global Vaccine Fund commits $150 Million in vaccines and funding over five years to 13 developing countries. Countries will receive financial and technical assistance in order to strengthen basic immunization systems and to introduce newer, under-used vaccines such as hepatitis B and Haemophilus influenzae type b (Hib). Some countries will receive support in both areas. Thus the growing support for vaccine development is likely to favor market growth.

The global vaccines market on the patient type is segmented into pediatric patients and adult patients. In 2018, the pediatric segment held a largest market share of 70.0% of the vaccines market, by patient type. This segment is also expected to dominate the market in 2027 as external immunization is necessary for the new borns. Moreover, vaccines have helped the children in staying healthy and been successful to save millions of lives for more than 50 years.

Some of the prominent players operating in vaccines market are PFIZER INC, GlaxoSmithKline plc, Merck & Co., Inc., Sanofi, Johnson & Johnson Services, Inc, Panacea Biotec Limited, Astellas Pharma Inc., NOVAVAX, INC., VBI Vaccines Inc, and Bavarian Nordic. The market players are focused towards bringing new and innovative products and services to sustain their position in the market. For instance, in December, 2018, The European Commission has granted marketing authorization for Dengvaxia, Sanofi's dengue vaccine. The marketing authorization follows the October 18, 2018, recommendation by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) to approve use of the dengue vaccine in European endemic areas. The developments performed by the companies are helping the market to grow in the coming years.
Global Vaccines Market, By Regions, 2018 (%)
 
Source: The Insight Partners Analysis

The report segments the global vaccines market as follows:

Global Vaccines Market - By Technology

  • Recombinant vaccines
  • Conjugate Vaccines
  • Live Attenuated Vaccines
  • Inactivated Vaccines
  • Toxoid Vaccines

Global Vaccines Market - By Disease Indication

  • DTP (diphtheria, tetanus, and pertussis)
  • Influenza
  • Hepatitis
  • Respiratory Syncytial Virus (RSV)
  • Other Diseases

Global Vaccines Market - By Route of Administration

  • Oral
  • Injectable
  • Other

Global Vaccines Market - By Patient Type

  • Adult Patients
  • Pediatric Patients

Global Vaccines Market - By Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
  • Asia Pacific (APAC)
    • Japan
    • China
    • India
    • Australia
    • South Korea
  • Middle East & Africa (MEA)
    • South Africa
    • UAE
    • Saudi Arabia
  • South & Central America (SCAM)
    • Brazil
    • Argentina
       

Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@reportsweb.com

 

Have a Question?


Recent Posts